EA200101112A1 - Синергическое действие амлодипина и метаболита аторвастатина как основа для комбинированной терапии - Google Patents

Синергическое действие амлодипина и метаболита аторвастатина как основа для комбинированной терапии

Info

Publication number
EA200101112A1
EA200101112A1 EA200101112A EA200101112A EA200101112A1 EA 200101112 A1 EA200101112 A1 EA 200101112A1 EA 200101112 A EA200101112 A EA 200101112A EA 200101112 A EA200101112 A EA 200101112A EA 200101112 A1 EA200101112 A1 EA 200101112A1
Authority
EA
Eurasian Patent Office
Prior art keywords
combination
amlodipine
atorvastatin
density lipoproteins
metabolitis
Prior art date
Application number
EA200101112A
Other languages
English (en)
Other versions
EA004435B1 (ru
Inventor
Р. Престон Мэсон
Original Assignee
Р. Престон Мэсон
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27494873&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200101112(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Р. Престон Мэсон filed Critical Р. Престон Мэсон
Publication of EA200101112A1 publication Critical patent/EA200101112A1/ru
Publication of EA004435B1 publication Critical patent/EA004435B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Сочетание амлодипина с аторвастатином или с метаболитом аторвастатина обладает синергическим антиокислительным действием на перекисное окисление липидов в человеческих липопротеинах низкой плотности и в мембранных везикулах, обогащенных полиненасыщенными жирными кислотами. Степень ингибирования этим сочетанием лекарств повреждений, вызванных оксирадикалами, при терапевтических количествах введенных лекарств нельзя было повторить при введении сочетания амлодипина с другими статинами или с природным антиоксидантом - витамином Е. Сделан вывод, что основой этой высокой активности являются химические структуры соединений и их молекулярные взаимодействия с фосфолипидными молекулами, что подтверждает анализ с помощью рентгеновского рассеяния. Эта комбинированная терапия может быть применена для лечения сердечно-сосудистых заболеваний, в особенности заболевания коронарных артерий, путем повышения устойчивости липопротеинов низкой плотности и мембран клеток сосудов к окислительной модификации.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200101112A 1999-04-23 2000-04-18 Синергическое действие амлодипина и метаболита аторвастатина как основа для комбинированной терапии EA004435B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13066599P 1999-04-23 1999-04-23
US14530599P 1999-07-23 1999-07-23
US15112199P 1999-08-27 1999-08-27
US16659299P 1999-11-19 1999-11-19
PCT/US2000/010465 WO2000064443A1 (en) 1999-04-23 2000-04-18 Synergistic effects of amlodipine and atorvastatin

Publications (2)

Publication Number Publication Date
EA200101112A1 true EA200101112A1 (ru) 2002-06-27
EA004435B1 EA004435B1 (ru) 2004-04-29

Family

ID=27494873

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200101112A EA004435B1 (ru) 1999-04-23 2000-04-18 Синергическое действие амлодипина и метаболита аторвастатина как основа для комбинированной терапии

Country Status (30)

Country Link
EP (1) EP1173172B1 (ru)
JP (1) JP2002542289A (ru)
KR (1) KR20020024581A (ru)
CN (1) CN1351492A (ru)
AP (1) AP2001002324A0 (ru)
AT (1) ATE314846T1 (ru)
AU (1) AU4647000A (ru)
BG (1) BG106115A (ru)
BR (1) BR0010689A (ru)
CA (1) CA2370639A1 (ru)
CZ (1) CZ20013793A3 (ru)
DE (1) DE60025344T2 (ru)
DK (1) DK1173172T3 (ru)
EA (1) EA004435B1 (ru)
EE (1) EE200100555A (ru)
ES (1) ES2256005T3 (ru)
HK (1) HK1043741A1 (ru)
HU (1) HUP0201016A3 (ru)
IL (1) IL146085A0 (ru)
IS (1) IS6118A (ru)
NO (1) NO20015128L (ru)
OA (1) OA11870A (ru)
PE (1) PE20010055A1 (ru)
PL (1) PL351408A1 (ru)
PT (1) PT1173172E (ru)
SK (1) SK15382001A3 (ru)
SV (1) SV2002000058A (ru)
TN (1) TNSN00085A1 (ru)
UY (1) UY26118A1 (ru)
WO (1) WO2000064443A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
CN100430057C (zh) * 2005-04-08 2008-11-05 石药集团中奇制药技术（石家庄）有限公司 左旋氨氯地平和阿托伐他汀的药物组合物
KR101467110B1 (ko) * 2013-08-01 2014-11-28 한국방송공사 코로나링을 구비한 지선애자

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385929A (en) * 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.

Also Published As

Publication number Publication date
AU4647000A (en) 2000-11-10
UY26118A1 (es) 2001-03-16
WO2000064443A9 (en) 2002-08-29
WO2000064443A1 (en) 2000-11-02
CA2370639A1 (en) 2000-11-02
KR20020024581A (ko) 2002-03-30
CN1351492A (zh) 2002-05-29
TNSN00085A1 (fr) 2005-11-10
HUP0201016A3 (en) 2003-03-28
SK15382001A3 (sk) 2002-05-09
SV2002000058A (es) 2002-02-05
PL351408A1 (en) 2003-04-22
HUP0201016A2 (hu) 2002-07-29
HK1043741A1 (zh) 2002-09-27
NO20015128D0 (no) 2001-10-19
PE20010055A1 (es) 2001-01-30
AP2001002324A0 (en) 2001-12-31
BR0010689A (pt) 2002-02-19
IL146085A0 (en) 2002-07-25
EP1173172A1 (en) 2002-01-23
BG106115A (bg) 2002-11-29
PT1173172E (pt) 2006-05-31
EE200100555A (et) 2002-12-16
JP2002542289A (ja) 2002-12-10
OA11870A (en) 2006-03-27
IS6118A (is) 2001-10-19
NO20015128L (no) 2001-12-20
ATE314846T1 (de) 2006-02-15
CZ20013793A3 (cs) 2002-05-15
EP1173172A4 (en) 2002-08-07
EP1173172B1 (en) 2006-01-04
DK1173172T3 (da) 2006-05-15
ES2256005T3 (es) 2006-07-16
EA004435B1 (ru) 2004-04-29
DE60025344T2 (de) 2006-09-28
DE60025344D1 (de) 2006-03-30

Similar Documents

Publication Publication Date Title
Hussein et al. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL
NO20073456L (no) Omega-3 fettsyrer og dyslipidemisk middel for lipidbehandling
Anraku et al. Antioxidant effects of a dietary supplement: Reduction of indices of oxidative stress in normal subjects by water-soluble chitosan
Rodriguez-Rodriguez et al. Triterpenic compounds from “orujo” olive oil elicit vasorelaxation in aorta from spontaneously hypertensive rats
Minville et al. Opioid-induced hyperalgesia in a mice model of orthopaedic pain: preventive effect of ketamine
EP2283837A3 (en) Docosahexaenoic acid for treating subclinical inflammation
AR046126A1 (es) Formulaciones farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos
Shimajiri et al. Synergistic antioxidant activity of milk sphingomyeline and its sphingoid base with α-tocopherol on fish oil triacylglycerol
WO2001021185A1 (es) Nuevas actividades farmacologicas de los extractos de curcuma longa
Hussein et al. Hypolipidemic effect of curcumin in hyper-cholesterolemic rats
JP4156841B2 (ja) ナイアシンの経皮送達用局所製剤および高脂血症の処置方法
DE602004019884D1 (de) Zubereitungen enthaltend mehrfach ungesättigte phospholipide, monoterpene und tryptophan und/oder phytol-derivate
EA200101112A1 (ru) Синергическое действие амлодипина и метаболита аторвастатина как основа для комбинированной терапии
EP1965791B1 (de) Neue kompositionen gegen alkyl-acyl-gpc, seine derivate und produkte
Vasilenko et al. Hypolipidemic properties of triterpenoids
Fauziah et al. Effect of Ethyl Acetate Extract of Penicillium citrinum from Xestopongia testudinaria on Blood Glucose Level, Insulin Concentration, and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).
Franiak-Pietryga et al. Anti-inflammatory and hypolipemic effects in vitro of simvastatin comparing to epicatechin in patients with type-2 hypercholesterolemia
JP6751868B2 (ja) 乳化組成物
ECSP003442A (es) Efectos sinergeticos de amlodipina y atorvastatina o metabolito de atorvastatina como una base para la terapia de combinacion
Waterhouse et al. From free radical scavengers to nucleophilic tone: a paradigm shift in nutraceutical effects of fruits and vegetables
Humaish et al. Comparison the Anti-atherogenic and hypolipidaemic effect of Cod liver oil, pomegranate seed oil and Rosuvastatin in hyperecholestrolemic rats
Wible Jr et al. Biodistribution of diclofenac following repeated topical applications of two diclofenac sodium formulations to minipigs
AR023569A1 (es) Efectos sinergicos de la amlodipina y atorvastatina o metabolitos de la atorvastatina, como base para una terapia combinada
Siddiqui et al. Efficacy of Herbal Coded Traditional Medicine Formulation “Lipitame” for Primary Hyperlipidemia
Lamponi et al. Journal of Integrative Medicine

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU